EVP and Chief Business Officer of Penumbra Inc (30-Year Financial, Insider Trades) Lynn Rothman (insider trades) sold 5,000 shares of PEN on 09/13/2019 at an average price of $150.02 a share. The total sale was $750,100.
Penumbra Inc designs, develops, manufactures and markets medical devices. The products of the company address ischemic stroke, hemorrhagic stroke and vascular conditions that can be treated through thrombectomy and embolization procedures. Penumbra Inc has a market cap of $5.28 billion; its shares were traded at around $151.62 with a P/E ratio of 505.40 and P/S ratio of 11.33. GuruFocus has detected 2 severe warning signs with Penumbra Inc. .
CEO Recent Trades:
- Chairman and CEO Adam Elsesser sold 8,000 shares of PEN stock on 09/11/2019 at the average price of $144.67. The price of the stock has increased by 4.8% since.
Directors and Officers Recent Trades:
- President, International James Robert Pray sold 10,008 shares of PEN stock on 09/13/2019 at the average price of $150.04. The price of the stock has increased by 1.05% since.
- EVP and Chief Business Officer Lynn Rothman sold 5,000 shares of PEN stock on 09/13/2019 at the average price of $150.02. The price of the stock has increased by 1.07% since.
- Director Harpreet Grewal sold 475 shares of PEN stock on 09/03/2019 at the average price of $144.81. The price of the stock has increased by 4.7% since.
- Director Bridget O'rourke sold 175 shares of PEN stock on 09/03/2019 at the average price of $145.88. The price of the stock has increased by 3.93% since.
- EVP and Chief Business Officer Lynn Rothman sold 5,000 shares of PEN stock on 08/19/2019 at the average price of $144.66. The price of the stock has increased by 4.81% since.
For the complete insider trading history of PEN, click here
.
